Effects of Platelet-Rich Plasma local injection in treatment of women with mild and moderate carpal tunnel syndrome

Phase 3

• Conditions: carpal tunnel syndrome.; Mononeuropathies of upper limb

• Registration Number: IRCT2017041513442N13
• Lead Sponsor: Vice chancellor for research,Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 41

Inclusion Criteria

patient with mild and moderate CTS confirmed by the presence of one or more of the following standard electrophysiological criteria: 1- prolonged distal motor latency (DML) (abnormal response is more than 4.2 millisecond) of Median nerve and 2- prolonged antidromic distal sensory latency (DSL) to the third digit (abnormal response is more than 3.6 millisecond); Exclusion criteria: Pregnancy; Severe degree CTS; Background metabolic diseases such as: diabetes mellitus; hypothyroidism; rheumatoid arthritis; Previous history of corticosteroid injection in Carpal Tunnel Syndrome; Severe atrophy of thenar muscles; cervical radiculopathy or significant polyneuropathy; Unwillingness to participate in the present study; patient younger than 20 or older than 65 years old; history or presence of cancer or malignant disorders; presence of immunosuppressive, autoimmune and platelet disorders; treatment with anticoagulant and anti-platelet medications 10 days before injection; use of NSAIDs 2 days before injection; use of systemic corticosteroids 2 weeks before PRP injections; hemoglobin measures of less than 12 g/dl and platelet counts of less than 150,000 per micro liter

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: Visual Analog Scale, that is from 0-10 and zero (0) means that you did not have any pain and ten (10) means that you had the worst pain imaginable.

Secondary Outcome Measures

Name	Time	Method
Median CMAP distal latency. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: Electrodiagnostic study.;Symptom severity. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: Boston/Levine symptome severity scale.;Median SNAP peak latency. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: Electrodiagnostic study.;Functional Status. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: boston questionaire.